View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Oct. 31, 2019
Document Information [Line Items]
Entity Registrant Name	LEMAITRE VASCULAR INC
Entity Central Index Key	0001158895
Trading Symbol	lmat
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		1,991,347
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 11,719	$ 26,318
Short-term marketable securities	33,177	21,668
Accounts receivable, net of allowances of $482 at September 30, 2019 and $399 at December 31, 2018	14,878	15,721
Inventory and other deferred costs	36,695	27,388
Prepaid expenses and other current assets	3,226	2,922
Total current assets	99,695	94,017
Property and equipment, net	14,070	14,102
Right-of-use leased assets	6,008
Goodwill	32,102	29,868
Other intangibles, net	16,765	13,692
Deferred tax assets	1,164	1,215
Other assets	210	194
Total assets	170,014	153,088
Liabilities and stockholders’ equity
Accounts payable	1,670	1,732
Accrued expenses	13,390	15,847
Acquisition-related obligations	2,597	2,179
Lease liabilities - short-term	1,666
Total current liabilities	19,323	19,758
Lease liabilities - long-term	4,755
Deferred tax liabilities	823	484
Other long-term liabilities	2,797	2,611
Total liabilities	27,698	22,853
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 21,495,306 shares at September 30, 2019, and 21,110,224 shares at December 31, 2018	215	211
Additional paid-in capital	103,673	98,442
Retained earnings	54,117	45,831
Accumulated other comprehensive loss	(4,894)	(3,900)
Treasury stock, at cost; 1, 515,378 shares at September 30, 2019 and 1,501,511 shares at December 31, 2018	(10,795)	(10,349)
Total stockholders’ equity	142,316	130,235
Total liabilities and stockholders’ equity	$ 170,014	$ 153,088

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts receivable, allowances	$ 482	$ 399
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	37,000,000	37,000,000
Common stock, shares issued (in shares)	21,495,306	21,110,224
Treasury stock, at cost (in shares)	1,515,378	1,501,511

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net Sales	$ 29,100	$ 24,165	$ 87,062	$ 77,179
Cost of sales	8,934	6,910	27,117	22,458
Gross profit	20,166	17,255	59,945	54,721
Sales and marketing	7,429	6,622	22,887	20,504
General and administrative	4,551	3,983	14,026	13,227
Research and development	2,281	2,037	6,777	5,850
Gain on divestiture				(5,876)
Total operating expenses	14,261	12,642	43,690	33,705
Income from operations	5,905	4,613	16,255	21,016
Other income (expense):
Interest income	193	192	574	452
Foreign currency gain (loss)	(208)	(75)	(338)	(275)
Income before income taxes	5,890	4,730	16,491	21,193
Provision for income taxes	706	416	3,170	4,275
Net income	$ 5,184	$ 4,314	$ 13,321	$ 16,918
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.26	$ 0.22	$ 0.68	$ 0.87
Diluted (in dollars per share)	$ 0.25	$ 0.21	$ 0.66	$ 0.84
Weighted-average shares outstanding:
Basic (in shares)	19,871	19,503	19,731	19,369
Diluted (in shares)	20,378	20,293	20,277	20,258
Cash dividends declared per common share (in dollars per share)	$ 0.085	$ 0.07	$ 0.255	$ 0.21

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net income	$ 5,184	$ 4,314	$ 13,321	$ 16,918
Other comprehensive income (loss):
Foreign currency translation adjustment, net	(1,072)	(308)	(1,125)	(1,204)
Unrealized gain (loss) on short-term marketable securities	(4)	33	131	11
Total other comprehensive income (loss)	(1,076)	(275)	(994)	(1,193)
Comprehensive income	$ 4,108	$ 4,039	$ 12,327	$ 15,725

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	20,745,041				1,480,101
Balance at Dec. 31, 2017	$ 207	$ 93,127	$ 28,333	$ (2,289)	$ (9,608)	$ 109,770
Net income			3,853			3,853
Other comprehensive income				283		283
Issuance of common stock for stock options exercised (in shares)	34,826
Issuance of common stock for stock options exercised	$ 1	292				293
Stock-based compensation expense		621				621
Repurchase of common stock at cost
Common stock dividend accrued			(1,350)			(1,350)
Balance (in shares) at Mar. 31, 2018	20,779,867				1,480,101
Balance at Mar. 31, 2018	$ 208	94,040	30,836	(2,006)	$ (9,608)	113,470
Balance (in shares) at Dec. 31, 2017	20,745,041				1,480,101
Balance at Dec. 31, 2017	$ 207	93,127	28,333	(2,289)	$ (9,608)	109,770
Net income						16,918
Other comprehensive income						(1,193)
Balance (in shares) at Sep. 30, 2018	21,080,465				1,498,603
Balance at Sep. 30, 2018	$ 211	97,727	41,178	(3,482)	$ (10,287)	125,347
Balance (in shares) at Mar. 31, 2018	20,779,867				1,480,101
Balance at Mar. 31, 2018	$ 208	94,040	30,836	(2,006)	$ (9,608)	113,470
Net income			8,751			8,751
Other comprehensive income				(1,201)		(1,201)
Issuance of common stock for stock options exercised (in shares)	56,215
Issuance of common stock for stock options exercised		446				446
Vested restricted stock units (in shares)	765
Vested restricted stock units
Stock-based compensation expense		636				636
Repurchase of common stock at cost (in shares)					149
Repurchase of common stock at cost					$ (5)	(5)
Common stock dividend accrued			(1,353)			(1,353)
Balance (in shares) at Jun. 30, 2018	20,836,847				1,480,250
Balance at Jun. 30, 2018	$ 208	95,122	38,234	(3,207)	$ (9,613)	120,744
Net income			4,314			4,314
Other comprehensive income				(275)		(275)
Issuance of common stock for stock options exercised (in shares)	192,487
Issuance of common stock for stock options exercised	$ 3	2,068				2,071
Vested restricted stock units (in shares)	51,131
Vested restricted stock units
Stock-based compensation expense		537				537
Repurchase of common stock at cost (in shares)					18,353
Repurchase of common stock at cost					$ (674)	(674)
Common stock dividend accrued			(1,370)			(1,370)
Balance (in shares) at Sep. 30, 2018	21,080,465				1,498,603
Balance at Sep. 30, 2018	$ 211	97,727	41,178	(3,482)	$ (10,287)	125,347
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	98,442	45,831	(3,900)	$ (10,349)	130,235
Net income			3,513			3,513
Other comprehensive income				(192)		(192)
Issuance of common stock for stock options exercised (in shares)	61,419
Issuance of common stock for stock options exercised	$ 1	478				479
Vested restricted stock units (in shares)	2,026
Vested restricted stock units
Stock-based compensation expense		746				746
Repurchase of common stock at cost (in shares)					926
Repurchase of common stock at cost					$ (21)	(21)
Common stock dividend accrued			(1,672)			(1,672)
Balance (in shares) at Mar. 31, 2019	21,173,669				1,502,437
Balance at Mar. 31, 2019	$ 212	99,666	47,672	(4,092)	$ (10,370)	133,088
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	98,442	45,831	(3,900)	$ (10,349)	130,235
Net income						13,321
Other comprehensive income						(994)
Balance (in shares) at Sep. 30, 2019	21,495,306				1,515,378
Balance at Sep. 30, 2019	$ 215	103,673	54,117	(4,894)	$ (10,795)	142,316
Balance (in shares) at Mar. 31, 2019	21,173,669				1,502,437
Balance at Mar. 31, 2019	$ 212	99,666	47,672	(4,092)	$ (10,370)	133,088
Net income			4,624			4,624
Other comprehensive income				274		274
Issuance of common stock for stock options exercised (in shares)	77,032
Issuance of common stock for stock options exercised	$ 1	530				531
Vested restricted stock units (in shares)	171
Vested restricted stock units
Stock-based compensation expense		694				694
Repurchase of common stock at cost (in shares)					1,008
Repurchase of common stock at cost					$ (2)	(2)
Common stock dividend accrued			(1,672)			(1,672)
Balance (in shares) at Jun. 30, 2019	21,250,872				1,503,445
Balance at Jun. 30, 2019	$ 213	100,890	50,624	(3,818)	$ (10,372)	137,537
Net income			5,184			5,184
Other comprehensive income				(1,076)		(1,076)
Issuance of common stock for stock options exercised (in shares)	208,821
Issuance of common stock for stock options exercised	$ 2	2,128				2,130
Vested restricted stock units (in shares)	35,613
Vested restricted stock units
Stock-based compensation expense		655				655
Repurchase of common stock at cost (in shares)					11,933
Repurchase of common stock at cost					$ (423)	(423)
Common stock dividend accrued			(1,691)			(1,691)
Balance (in shares) at Sep. 30, 2019	21,495,306				1,515,378
Balance at Sep. 30, 2019	$ 215	$ 103,673	$ 54,117	$ (4,894)	$ (10,795)	$ 142,316

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities
Net income	$ 13,321	$ 16,918
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,975	3,108
Stock-based compensation	2,095	1,794
Fair value adjustment to contingent consideration obligations	123	(24)
Provision for doubtful accounts	289	209
Provision for inventory write-downs	508	298
Gain on divestitures		(5,876)
Foreign currency transaction loss	62	126
Changes in operating assets and liabilities:
Accounts receivable	268	1,552
Inventory and other deferred costs	(9,576)	(3,061)
Prepaid expenses and other assets	(449)	(1,764)
Accounts payable and other liabilities	(2,031)	(345)
Net cash provided by operating activities	8,585	12,935
Investing activities
Purchases of property and equipment and other assets	(2,361)	(1,764)
Purchases of short-term marketable securities	(18,378)	(15,948)
Sales of short-term marketable securities	7,000	13,000
Payments related to acquisitions	(6,815)	(11,000)
Proceeds from divestuture		7,400
Net cash used in investing activities	(20,554)	(8,312)
Financing activities
Payments of deferred acquisition consideration	(59)	(1,171)
Proceeds from issuance of common stock	3,138	2,809
Purchase of treasury stock	(446)	(678)
Common stock cash dividend paid	(5,035)	(4,073)
Net cash provided by financing activities	(2,402)	(3,113)
Effect of exchange rate changes on cash and cash equivalents	(228)	(502)
Net increase in cash and cash equivalents	(14,599)	1,008
Cash and cash equivalents at beginning of period	26,318	19,096
Cash and cash equivalents at end of period	$ 11,719	$ 20,104

Note 1 - Organization and Basis for Presentation

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Organization and Basis for Presentation

Description of Business

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a

single

segment in which our principal product lines include the following: anastomotic clips, angioscopes, biologic vascular grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, surgical glue, synthetic vascular grafts and valvulotomes. Our offices are located in Burlington, Massachusetts; Fox River Grove, Illinois; Chandler, Arizona; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Saint-Etienne, France; Hereford, England; North Melbourne, Australia; Tokyo, Japan; Shanghai, China; and Singapore.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form

-Q and Article

of Regulation S-

Accordingly, they do

not

include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results

may

differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the

nine

months ended

September 30, 2019

are

not

necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended

December

31,

2018,

including the notes thereto, included in our Form

-K filed with the Securities and Exchange Commission (SEC) on

March

11,

2019.

Consolidation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met.

We recognize revenue under the provisions of ASU

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. The core principle of Topic

606

is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step

Identify the contract with a customer

Step

Identify the performance obligations in the contract

Step

Determine the transaction price

Step

Allocate the transaction price

Step

Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic

606

to account for these activities as fulfillment costs and

not

as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are

not

accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to

one

or more, but

not

all, of the performance obligations.

We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	($ in thousands)				($ in thousands)

Americas	$	17,698	$	14,941	$	51,584	$	46,885
Europe, Middle East and Africa		9,452		7,857		29,479		25,685
Asia/Pacific Rim		1,950		1,366		5,999		4,609
Total	$	29,100	$	24,164	$	87,062	$	77,179

Except as discussed in Note

we do

not

carry any contract assets or contract liabilities, as there are generally

unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have

not

satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within

days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is

significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products

may

be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least

months remaining prior to its expiration date, or

twelve

months for our hospital customers in Europe, and generally be returned within

days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has

not

been material. Nevertheless, we provide for an allowance for future sales returns based on historical returns experience, which requires judgment. Our cost of replacing defective products has

not

been material and is accounted for at the time of replacement.

Recent Accounting Pronouncements

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

. Under the new guidance, we are required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. As allowed by the standard, we elected to use the transition option

not

to apply the new lease standard to comparative periods but instead to recognize a cumulative-effect adjustment to retained earnings as of the date of adoption,

January 1, 2019.

Upon adoption of this standard, we recognized lease liabilities of

$7.0

million and right-of-use assets in the amount of

$6.5

million (net of the reversal of a previously recorded deferred rent liability of

$0.5

million). There was

cumulative-effect adjustment to retained earnings required. Additional disclosures required under the new standard are included in Note

to these financial statements.

August 2018,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU)

2018

15,

Intangibles—Goodwill and Other—Internal-Use Software (Subtopic

350

)

, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

August 2018,

the FASB issued ASU

2018

Fair Value Measurement (Topic

820

), which modifies the disclosure requirements for fair value measurements. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

January 2017,

the FASB issued ASU

2017

04,

which, among other provisions, eliminates “step

2”

from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should

not

exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

June 2016,

the FASB issued ASU

No.

2016

13,

Financial Instruments – Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments (“ASU

2016

13”

), which modifies the measurement of expected credit losses of certain financial instruments, including accounts receivable. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

Note 2 - Income Tax Expense

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Income Tax Expense

As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is

not

more likely than

not,

we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do

not

provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.

We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and

may

be subject to audits from various tax authorities. Management’s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense. Our

2019

income tax expense varies from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, different statutory rates from our foreign subsidiaries, and discrete stock option exercises. Our

2018

income tax expense varied from the statutory rate mainly due to federal and state tax credits, permanent items, different statutory rates from our foreign entities, and discrete stock option exercises.

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of

September 30, 2019,

the gross amount of unrecognized tax benefits exclusive of interest and penalties was

$766,000.

We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until

2026.

A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:

	Nine months ended September 30, 2019
	(in thousands)
Unrecognized tax benefits as of December 31, 2018	$	711
Additions for tax positions of current year		55
Additions for tax positions of prior years		-
Reductions for settlements with taxing authorities		-
Reductions for lapses of the applicable statutes of limitations		-
Unrecognized tax benefits as of September 30, 2019	$	766

As of

September 30, 2019,

a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:

United States	2016 and forward
Foreign	2012 and forward

Note 3 - Inventories and Other Deferred Costs

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Inventory and Other Deferred Costs Disclosure [Text Block]

Inventories and Other Deferred Costs

Inventories and other deferred costs consist of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Raw materials	$	4,916	$	4,085
Work-in-process		5,037		5,095
Finished products		22,331		16,391
Other deferred costs		4,411		1,817

Total inventory and other deferred costs	$	36,695	$	27,388

We had inventory on consignment of

$1.8

million and

$1.7

million at

September 30, 2019

and

December

31,

2018,

respectively.

Other deferred costs relate to our RestoreFlow allograft offering and include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the vascular tissues we preserve are

not

held as inventory, and the costs we incur to procure and process them are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials and facilities costs. General and administrative expenses and selling expenses associated with the provision of these services are expensed as incurred.

Note 4 - Acquisitions and Divestitures

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Business Combination Disclosure [Text Block]

Acquisitions and Divestitures

Our acquisitions are accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is

not

included, as the impact is immaterial.

With the exception of Cardial discussed below, our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products and services, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure. The fair market valuations associated with these transactions fall within Level

of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates. Our assumptions associated with these Level

valuations are discussed below and in Note

to these financial statements.

Tru-Incise Valve Cutter

July 12, 2019,

we entered into an agreement with UreSil, LLC, an Illinois limited liability company, to purchase the remaining assets of their Tru-Incise valve cutter business, including distribution rights in the United States. We also entered into a transition services agreement under which UreSil, LLC will continue to manufacture the acquired products for us for a specified time, until we transition the full manufacturing process to our Burlington, Massachusetts facilities.

The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, and customer and supplier information, was

$8.0

million. Of this amount,

$6.8

million was paid at closing, with

three

follow-on payments

$0.4

million each due on the first,

second

and

third

anniversaries of the closing date. The deferred amounts totaling

$1.2

million were recorded at an acquisition-date fair value of

$1.1

million using a discount rate of

4.19%

to reflect the time value of money between the acquisition date and the payment due dates. There are

contingencies associated with these holdback payments, although they

may

be reduced for certain post-closing claims.

The following table summarizes the preliminary purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	827
Equipment and supplies		70
Intangible assets		4,727
Goodwill		2,314

Purchase price	$	7,938

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over

years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
	Allocated Fair Value		Average Useful Life
	(in thousands)		(in years)
Customer relationships	$	3,865		16.0
Intellectual property		558		7.0
Non-compete agreement		201		5.0
Tradenames		103		7.0

Total intangible assets	$	4,727

The weighted-average amortization period of the acquired intangible assets was

14.2

years.

Cardial

October 22, 2018,

through a newly created subsidiary LeMaitre Cardial SAS, we entered into an agreement to acquire the business assets of Cardial, a company located in Saint-Etienne, France. The Cardial business consists of the manufacturing of polyester vascular grafts, valvulotomes, surgical glue and original equipment manufacturing (OEM) services. On the same date, the parties entered into a separate agreement under which LeMaitre Cardial SAS purchased the building and land previously owned by Cardial.

The purchase price for the acquired assets, including the land and building, inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was

€2.0

million (

$2.3

million). At closing,

€1.1

million (

$1.3

million) was paid in cash, and

€0.5

million (

$0.5

million) of liabilities were assumed by LeMaitre Cardial SAS. Another

€0.4

million (

$0.4

million) is due in

two

installments, half to be paid

twelve

months after the closing date, and half

eighteen

months after the closing date. There are

contingencies associated with these holdback payments, although they

may

be reduced depending upon the results of a reconciliation of the value of inventory transferred, as outlined in the agreement, or for certain post-closing claims.

The following table summarizes the preliminary purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	€	2,419
Land and building		750
Equipment and supplies		94
Intangible assets		623
Bargain purchase gain		(1,946	)

Purchase price	€	1,940

The bargain purchase gain was recorded to reflect the excess of the net assets acquired over the purchase price. We recorded deferred taxes on this gain of

€0.5

million (

$0.6

million), resulting in a net gain of

€1.4

million (

$1.6

million).

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)		(in years)
Customer relationships	€	250		16.0
Intellectual property		237		5.0
Non-compete agreement		46		5.0
Tradenames		90		5.0

Total intangible assets	€	623

The weighted-average amortization period of the acquired intangible assets was

9.4

years.

Applied Medical

Clot Management Business

September 20, 2018,

we entered into an agreement to acquire the assets of the embolectomy catheter business of Applied Medical Resources Corporation (Applied). The acquired business consists of several embolectomy, thrombectomy and irrigation catheter product lines which are sold worldwide (approximately

60%

in the U.S. and

40%

outside the U.S.). On the same date, we entered into a transition services agreement under which Applied will manufacture and supply us with inventory for a period of

twelve

months, unless extended by both parties.

The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was

$14.2

million. Of this amount,

$11

million was paid at closing, with another

million due

months following the closing date, and the final

$1.2

million due

months following the closing date. The deferred amounts totaling

$3.2

million were recorded at an acquisition-date fair value of

$3.0

million using a discount rate of

3.75%

to reflect the time value of money between the acquisition date and the payment due dates. There are

contingencies associated with these holdback payments, although they

may

be reduced for certain post-closing claims.

The following table summarizes the purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	739
Equipment and supplies		416
Intangible assets		6,527
Goodwill		6,361

Purchase price	$	14,043

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over

years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)		(in years)
Customer relationships	$	4,475		16.0
Intellectual property		1,316		7.0
Non-compete agreement		530		5.0
Tradenames		206		7.0

Total intangible assets	$	6,527

The weighted-average amortization period of the acquired intangible assets was

13.0

years.

Reddick Divestiture

April

2018,

we entered into an agreement to sell the inventory, intellectual property and other assets associated exclusively with our Reddick cholangiogram catheter and Reddick-Saye screw product lines for

$7.4

million to Specialty Surgical Instrumentation. Concurrent with this divestiture we entered into a transition services agreement under which we will continue to manufacture and supply these products to the buyer for a period of up to

two

years unless extended by both parties, as well as a balloon supply agreement under which we will supply balloons, a component of the cholangiogram catheters, to the buyer for a period of up to

six

years unless extended by both parties. We recorded a gain during the quarter ended

June 30, 2018

in connection with these agreements of

$5.9

million. The following table summarizes the allocation of consideration received:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue - transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

Under the terms of the transition services agreement, we agreed to manufacture the Reddick products for the buyer at prices at or in some cases below our cost. We allocated a portion of the consideration received to this agreement to reflect it at fair value and recorded it as deferred revenue. As the products were sold to the buyer, we amortized a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. This arrangement ended by mutual agreement during the quarter ended

September 30, 2019,

and all remaining deferred revenue was recognized.

Subsequent Event

October 11, 2019

we acquired the biologic cardiac and vascular patch business of Admedus Ltd for

$15.5

million, of which

$14.2

million was paid at closing and

$1.3

million is due in

two

post-closing installments, as well as potential earnout payments of

$7.8

million payable based upon performance of the acquired business as well as other milestones. We also entered into a license agreement for the tissue processing technology limited to the acquired CardioCel and VascuCel product lines, and a transition services agreement under which Admedus will continue to manufacture the products for up to

three

years while we transition manufacturing to Burlington.

Note 5 - Goodwill and Other Intangibles

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Other Intangibles

Goodwill consists of the following as of

September 30, 2019:

	(in thousands)
Balance at December 31, 2018	$	29,868

Additions for acquisitions		2,314
Effects of currency exchange		(80	)

Balance at September 30, 2019	$	32,102

Other intangible assets consist of the following:

	September 30, 2019						December 31, 2018
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	12,286	$	6,518	$	5,768	$	11,728	$	5,726	$	6,002
Trademarks, tradenames and licenses		2,349		1,661		688		2,246		1,561		685
Customer relationships		13,928		4,398		9,530		10,065		3,806		6,259
Other intangible assets		2,342		1,563		779		2,145		1,399		746

Total identifiable intangible assets	$	30,905	$	14,140	$	16,765	$	26,184	$	12,492	$	13,692

These intangible assets are being amortized over their useful lives ranging from

years. The weighted-average amortization period for these intangibles as of

September 30, 2019

11.0

years. Amortization expense is included in general and administrative expense and was as follows for the periods indicated.

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)

Amortization expense	$	600	$	380	$	1,711	$	1,213

We estimate that amortization expense for the remainder of

2019

and for each of the

five

succeeding fiscal years will be as follows:

	Year ended December 31,
	2019		2020		2021		2022		2023		2024
	(in thousands)

Amortization expense	$	573	$	2,233	$	2,000	$	1,796	$	1,722	$	1,541

Note 6 - Leases

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

Leases

We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do

not

meet the criteria for finance leases. Our principal worldwide executive, distribution, and manufacturing operations are located at

three

adjacent

27,098

square foot,

27,289

square foot and

15,642

square foot leased facilities, as well as a

fourth

nearby

12,878

square foot leased facility, in Burlington, Massachusetts. Each of our Burlington leases expires in

December 2023.

In addition, our international operations are headquartered at a

16,470

square foot leased facility located in Sulzbach, Germany, including approximately

3,630

square feet added in

2019,

under a lease which expires in

August 2023.

This lease contains

two five

-year renewal options. In addition, we have smaller long-term leased sales, marketing and other facilities located in Arizona, Japan, Canada, Australia, Singapore and China, and short-term leases in Italy, Spain and Illinois. Our lease in Canada contains a

five

-year renewal option exercisable in

February 2023.

Our leases in Germany and Australia are subject to periodic rent increases based on increases in the consumer price index as measured each

September

and

May,

respectively, with such increases applicable to the subsequent

twelve

months of lease payments.

None

of our noncancelable lease payments include non-lease components such as maintenance contracts; we generally reimburse the landlord for direct operating costs associated with the leased space. We have

subleases, and there are

residual value guarantees associated with, or restrictive covenants imposed by, any of our leases. There were

assets held under capital leases at

September 30, 2019.

October 29, 2019,

our

four

Burlington, Massachusetts leases were extended through

December 2030,

under terms substantially similar to the existing leases.

We also lease automobiles under operating leases in the U.S. as well as certain of our international subsidiaries. The terms of these leases are generally

three

years, with older vehicles replaced by newer vehicles from time to time.

As discussed above under Recent Accounting Pronouncements, on

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets was the estimation of a discount rate; because we have

debt we have

incremental borrowing rate to reference. We therefore estimated an incremental borrowing rate using quotes from potential lenders as the primary inputs, augmented by other available information. The resulting rate selected was

5.25%.

We determined that it was appropriate to apply this single rate to our portfolio of leases worldwide, as the lease terms and conditions are substantially similar, and because we believe our subsidiaries would be unable to obtain borrowings on their own without a commitment of parent company support.

Additional information with respect to our leases is as follows:

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
	(in thousands)		(in thousands)

Lease cost
Operating lease cost	$	486	$	1,340
Short-term lease cost		71		203
Total lease cost	$	557	$	1,543

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	498	$	1,457

Right-of-use assets obtained in exchange for new operating leae liabilities	$	69	$	879

Weighted average remaining lease term - operating leases (years)				4.2

Weighted average discount rate - operating leases				5.25	%

September 30, 2019,

the minimum noncancelable operating lease rental commitments with initial or remaining terms of more than

one

year are as follows:

Remainder of 2019	$	533
Year ending December 31,
2020		1,992
2021		1,854
2022		1,537
2023		1,242
Adjustment to net present value as of September 30, 2019		(737	)

Minimum noncancelable lease liability	$	6,421

Note 7 - Accrued Expenses and Other Long-term Liabilities

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]

Accrued Expenses and Other Long-term Liabilities

Accrued expenses consist of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Compensation and related taxes	$	7,086	$	7,973
Income and other taxes		1,347		2,927
Professional fees		142		43
Deferred revenue		-		552
Other		4,815		4,352

Total	$	13,390	$	15,847

As discussed in Note

above, deferred revenue related to our divestiture of the Reddick product line and an associated transition services agreement that we entered into at the time of the divestiture, under which we agreed to manufacture and sell product to the buyer at prices at or below our cost. We allocated a portion of the consideration received from the divestiture to this transition services agreement to reflect it at fair value and recorded it as deferred revenue. As the products were sold to the buyer, we amortized a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. This arrangement was completed during the quarter ended

September 30, 2019:

	September 30, 2019
	(in thousands)
Balance at December 31, 2018	$	552

Revenue recognized upon satisfaction of performance obligations in the period		(552	)

Ending balance	$	-

Other long-term liabilities consist of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Aquisition-related liabilities	$	2,089	$	1,326
Deferred rent		-		530
Income taxes		561		559
Other		147		196

Total	$	2,797	$	2,611

Note 8 - Segment and Enterprise-wide Disclosures

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Segment and Enterprise-Wide Disclosures

Under Accounting Standards Codification Topic

280,

Segment Reporting

, operating segments are defined as components of an enterprise for which separate, discrete financial information is available and evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as

one

operating segment.

discrete operating information is prepared by us except for sales by product line and by legal entity for local reporting purposes.

Most of our revenues are generated in the United States, Germany, and other European countries as well as in Canada, Japan and China. Substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
United States	$	16,251	$	13,937	$	47,015	$	43,620
Germany		3,074		3,058		9,346		9,421
Other countries		9,775		7,170		30,701		24,138

Net Sales	$	29,100	$	24,165	$	87,062	$	77,179

Note 9 - Share-based Compensation

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

Share-based Compensation

Our Third Amended and Restated

2006

Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards and deferred stock awards to our officers, employees, directors and consultants. The components of share-based compensation expense were as follows:

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Stock option awards	$	378	$	331	$	1,257	$	1,111
Restricted stock units		277		206		838		683

Total share-based compensation	$	655	$	537	$	2,095	$	1,794

Stock-based compensation is included in our statements of operations as follows:

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Cost of sales	$	75	$	61	$	233	$	209
Sales and marketing		155		155		459		429
General and administrative		356		266		1,194		967
Research and development		69		55		209		189

Total stock-based compensation	$	655	$	537	$	2,095	$	1,794

We did

not

grant any options during the

nine

-month periods ended

September 30, 2019

2018.

Awards of restricted stock units during both periods were immaterial.

We issued approximately

385,000

and

329,000

shares of common stock following the exercise or vesting of underlying stock options or restricted stock units during the

nine

months ended

September 30, 2019

and

2018,

respectively.

Note 10 - Net Income Per Share

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

10.

Net Income per Share

The computation of basic and diluted net income per share was as follows:

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands, except per share data)				(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	5,184	$	4,314	$	13,321	$	16,918

Weighted average shares outstanding		19,871		19,503		19,731		19,369

Basic earnings per share	$	0.26	$	0.22	$	0.68	$	0.87

Diluted:
Net income available for common stockholders	$	5,184	$	4,314	$	13,321	$	16,918

Weighted-average shares outstanding		19,871		19,503		19,731		19,369
Common stock equivalents, if dilutive		507		790		546		889
Shares used in computing diluted earnings per common share		20,378		20,293		20,277		20,258

Diluted earnings per share	$	0.25	$	0.21	$	0.66	$	0.84

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		210		212		488		213

Note 11 - Stockholders' Equity

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

11.

Stockholders’ Equity

Share Repurchase Program

February 14, 2019,

our Board of Directors authorized the repurchase of up to

$10.0

million of the Company’s common stock through transactions on the open market, in privately negotiated purchases or otherwise. The repurchase program

may

be suspended or discontinued at any time and will conclude on

February 14, 2020,

unless extended by the Board. To date we have

not

made any repurchases under this program.

Dividends

February 2011,

our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2019
March 22, 2019	April 5, 2019	$	0.085	$	1,672
May 22, 2019	June 5, 2019	$	0.085	$	1,672
August 21, 2019	September 5, 2019	$	0.085	$	1,691
Fiscal Year 2018
March 22, 2018	April 5, 2018	$	0.070	$	1,351
May 22, 2018	June 7, 2018	$	0.070	$	1,353
August 22, 2018	September 6, 2018	$	0.070	$	1,369
November 20, 2018	December 6, 2018	$	0.070	$	1,372

October 21, 2019

our Board of Directors approved a quarterly cash dividend on our common stock of

$0.085

per share payable on

December 5, 2019

to stockholders of record at the close of business on

November 20, 2019

which will total approximately

$1.7

million.

Note 12 - Supplemental Cash Flow Information

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Cash Flow, Supplemental Disclosures [Text Block]

12.

Sup

plemental Cash Flow Information

	Nine Months Ended
	September 30,
	2019		2018
	(in thousands)
Cash paid for income taxes, net	$	4,605	$	5,086

Note 13 - Fair Value Measurements

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Fair Value Disclosures [Text Block]

13.

Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in

one

of the following

three

categories:

•

Level

— Quoted prices in active markets for identical assets or liabilities.

•

Level

— Observable inputs other than quoted prices included in Level

such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are

not

active; or other inputs that are observable or can be corroborated by observable market data.

•

Level

— Unobservable inputs that are supported by little or

market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Level

assets being measured at fair value on a recurring basis as of

September 30, 2019

included our short-term investment mutual fund account.

We had

Level

assets being measured at fair value on a recurring basis as of

September 30, 2019.

Several of our assets and liabilities related to prior acquisitions were measured using Level

techniques. During

2016,

we recorded contingent liabilities associated with our acquisitions of the RestoreFlow allograft and ProCol biologic graft businesses. In the case of the RestoreFlow allograft acquisition, the agreement included the potential for us to pay up to

$5.1

million of additional consideration, with

$1.1

million contingent on the continued employment by LeMaitre Vascular of certain retained employees, and another

$4.0

million contingent on the achievement of specified levels of revenues in the

first

and

months following the acquisition date. This additional consideration was initially valued in total at

$1.0

million and was being re-measured each reporting period until the payment requirement ended, with any adjustments reported in income from operations. The

first

portion related to continued employment by LeMaitre Vascular of retained individuals was paid during

2018.

The amounts attributable to achieving specified levels of revenue following the acquisition date were

not

paid as the associated revenue metrics were

not

achieved. In the case of ProCol, additional consideration was payable to the former shareholders for a

three

-year period following the closing, calculated at

10%

of ProCol revenues. This additional consideration was initially valued at

$0.3

million and was being re-measured each reporting period until the payment requirement ended, with any adjustments reported in income from operations. The following table provides a rollforward of the fair value of these liabilities, as determined by Level

unobservable inputs including management’s forecast of future revenues for these acquired businesses, as well as, in the case of the RestoreFlow allograft acquisition, management’s estimate of the likelihood of continued employment of certain retained employees.

	Nine months ended
	September 30,
	2019			2018
	(in thousands)
Beginning balance	$	72		$	1,301
Additions		-			-
Payments		(59	)		(1,171	)
Change in fair value included in earnings		(13	)		(24	)

Ending balance	$	-		$	106

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 14 - Accumulated Other Comprehensive Loss

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Comprehensive Income (Loss) Note [Text Block]

14.

Accumulated Other Comprehensive Loss

Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation for the

nine

months ended

September 30, 2019

and

2018

were as follows:

	Nine months ended
	September 30,
	2019			2018
	(in thousands)
Beginning balance	$	(3,900	)	$	(2,289	)

Other comprehensive income (loss) before reclassifications		(994	)		(1,193	)
Amounts reclassified from accumulated other comprehensive loss		-			-

Ending Balance	$	(4,894	)	$	(3,482	)

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

-Q and Article

of Regulation S-

Accordingly, they do

not

may

nine

months ended

September 30, 2019

are

not

December

31,

2018,

including the notes thereto, included in our Form

-K filed with the Securities and Exchange Commission (SEC) on

March

11,

2019.

Consolidation, Policy [Policy Text Block]

Consolidation

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

We recognize revenue under the provisions of ASU

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. The core principle of Topic

606

Step

Identify the contract with a customer

Step

Identify the performance obligations in the contract

Step

Determine the transaction price

Step

Allocate the transaction price

Step

Recognize revenue when or as the entity satisfies a performance obligation

606

to account for these activities as fulfillment costs and

not

as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are

not

one

or more, but

not

all, of the performance obligations.

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	($ in thousands)				($ in thousands)

Americas	$	17,698	$	14,941	$	51,584	$	46,885
Europe, Middle East and Africa		9,452		7,857		29,479		25,685
Asia/Pacific Rim		1,950		1,366		5,999		4,609
Total	$	29,100	$	24,164	$	87,062	$	77,179

Except as discussed in Note

we do

not

carry any contract assets or contract liabilities, as there are generally

unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have

not

days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is

Customers returning products

may

months remaining prior to its expiration date, or

twelve

months for our hospital customers in Europe, and generally be returned within

days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has

not

been material. Nevertheless, we provide for an allowance for future sales returns based on historical returns experience, which requires judgment. Our cost of replacing defective products has

not

been material and is accounted for at the time of replacement.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

not

to apply the new lease standard to comparative periods but instead to recognize a cumulative-effect adjustment to retained earnings as of the date of adoption,

January 1, 2019.

Upon adoption of this standard, we recognized lease liabilities of

$7.0

million and right-of-use assets in the amount of

$6.5

million (net of the reversal of a previously recorded deferred rent liability of

$0.5

million). There was

cumulative-effect adjustment to retained earnings required. Additional disclosures required under the new standard are included in Note

to these financial statements.

August 2018,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU)

2018

15,

Intangibles—Goodwill and Other—Internal-Use Software (Subtopic

350

)

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

August 2018,

the FASB issued ASU

2018

Fair Value Measurement (Topic

820

), which modifies the disclosure requirements for fair value measurements. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

January 2017,

the FASB issued ASU

2017

04,

which, among other provisions, eliminates “step

2”

not

exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

June 2016,

the FASB issued ASU

No.

2016

13,

Financial Instruments – Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments (“ASU

2016

13”

), which modifies the measurement of expected credit losses of certain financial instruments, including accounts receivable. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

Note 1 - Organization and Basis for Presentation (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	($ in thousands)				($ in thousands)

Americas	$	17,698	$	14,941	$	51,584	$	46,885
Europe, Middle East and Africa		9,452		7,857		29,479		25,685
Asia/Pacific Rim		1,950		1,366		5,999		4,609
Total	$	29,100	$	24,164	$	87,062	$	77,179

Note 2 - Income Tax Expense (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	Nine months ended September 30, 2019
	(in thousands)
Unrecognized tax benefits as of December 31, 2018	$	711
Additions for tax positions of current year		55
Additions for tax positions of prior years		-
Reductions for settlements with taxing authorities		-
Reductions for lapses of the applicable statutes of limitations		-
Unrecognized tax benefits as of September 30, 2019	$	766

Note 3 - Inventories and Other Deferred Costs (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30, 2019		December 31, 2018
	(in thousands)
Raw materials	$	4,916	$	4,085
Work-in-process		5,037		5,095
Finished products		22,331		16,391
Other deferred costs		4,411		1,817

Total inventory and other deferred costs	$	36,695	$	27,388

Note 4 - Acquisitions and Divestitures (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	Allocated
	Fair Value
	(in thousands)
Inventory	$	827
Equipment and supplies		70
Intangible assets		4,727
Goodwill		2,314

Purchase price	$	7,938

	Allocated
	Fair Value
	(in thousands)
Inventory	€	2,419
Land and building		750
Equipment and supplies		94
Intangible assets		623
Bargain purchase gain		(1,946	)

Purchase price	€	1,940

	Allocated
	Fair Value
	(in thousands)
Inventory	$	739
Equipment and supplies		416
Intangible assets		6,527
Goodwill		6,361

Purchase price	$	14,043

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

			Weighted
	Allocated Fair Value		Average Useful Life
	(in thousands)		(in years)
Customer relationships	$	3,865		16.0
Intellectual property		558		7.0
Non-compete agreement		201		5.0
Tradenames		103		7.0

Total intangible assets	$	4,727

	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)		(in years)
Customer relationships	€	250		16.0
Intellectual property		237		5.0
Non-compete agreement		46		5.0
Tradenames		90		5.0

Total intangible assets	€	623

	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)		(in years)
Customer relationships	$	4,475		16.0
Intellectual property		1,316		7.0
Non-compete agreement		530		5.0
Tradenames		206		7.0

Total intangible assets	$	6,527

Disposal Groups, Including Discontinued Operations [Table Text Block]

	Allocated
	Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue - transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Note 5 - Goodwill and Other Intangibles (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Goodwill [Table Text Block]

	(in thousands)
Balance at December 31, 2018	$	29,868

Additions for acquisitions		2,314
Effects of currency exchange		(80	)

Balance at September 30, 2019	$	32,102

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	September 30, 2019						December 31, 2018
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	12,286	$	6,518	$	5,768	$	11,728	$	5,726	$	6,002
Trademarks, tradenames and licenses		2,349		1,661		688		2,246		1,561		685
Customer relationships		13,928		4,398		9,530		10,065		3,806		6,259
Other intangible assets		2,342		1,563		779		2,145		1,399		746

Total identifiable intangible assets	$	30,905	$	14,140	$	16,765	$	26,184	$	12,492	$	13,692

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)

Amortization expense	$	600	$	380	$	1,711	$	1,213

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	Year ended December 31,
	2019		2020		2021		2022		2023		2024
	(in thousands)

Amortization expense	$	573	$	2,233	$	2,000	$	1,796	$	1,722	$	1,541

Note 6 - Leases (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Lease, Cost [Table Text Block]

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
	(in thousands)		(in thousands)

Lease cost
Operating lease cost	$	486	$	1,340
Short-term lease cost		71		203
Total lease cost	$	557	$	1,543

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	498	$	1,457

Right-of-use assets obtained in exchange for new operating leae liabilities	$	69	$	879

Weighted average remaining lease term - operating leases (years)				4.2

Weighted average discount rate - operating leases				5.25	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Remainder of 2019	$	533
Year ending December 31,
2020		1,992
2021		1,854
2022		1,537
2023		1,242
Adjustment to net present value as of September 30, 2019		(737	)

Minimum noncancelable lease liability	$	6,421

Note 7 - Accrued Expenses and Other Long-term Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2019		December 31, 2018
	(in thousands)
Compensation and related taxes	$	7,086	$	7,973
Income and other taxes		1,347		2,927
Professional fees		142		43
Deferred revenue		-		552
Other		4,815		4,352

Total	$	13,390	$	15,847

Contract with Customer, Asset and Liability [Table Text Block]

	September 30, 2019
	(in thousands)
Balance at December 31, 2018	$	552

Revenue recognized upon satisfaction of performance obligations in the period		(552	)

Ending balance	$	-

Other Noncurrent Liabilities [Table Text Block]

	September 30, 2019		December 31, 2018
	(in thousands)
Aquisition-related liabilities	$	2,089	$	1,326
Deferred rent		-		530
Income taxes		561		559
Other		147		196

Total	$	2,797	$	2,611

Note 8 - Segment and Enterprise-wide Disclosures (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
United States	$	16,251	$	13,937	$	47,015	$	43,620
Germany		3,074		3,058		9,346		9,421
Other countries		9,775		7,170		30,701		24,138

Net Sales	$	29,100	$	24,165	$	87,062	$	77,179

Note 9 - Share-based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Share-based Payment Arrangement, Cost by Plan [Table Text Block]

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Stock option awards	$	378	$	331	$	1,257	$	1,111
Restricted stock units		277		206		838		683

Total share-based compensation	$	655	$	537	$	2,095	$	1,794

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
Cost of sales	$	75	$	61	$	233	$	209
Sales and marketing		155		155		459		429
General and administrative		356		266		1,194		967
Research and development		69		55		209		189

Total stock-based compensation	$	655	$	537	$	2,095	$	1,794

Note 10 - Net Income Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands, except per share data)				(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	5,184	$	4,314	$	13,321	$	16,918

Weighted average shares outstanding		19,871		19,503		19,731		19,369

Basic earnings per share	$	0.26	$	0.22	$	0.68	$	0.87

Diluted:
Net income available for common stockholders	$	5,184	$	4,314	$	13,321	$	16,918

Weighted-average shares outstanding		19,871		19,503		19,731		19,369
Common stock equivalents, if dilutive		507		790		546		889
Shares used in computing diluted earnings per common share		20,378		20,293		20,277		20,258

Diluted earnings per share	$	0.25	$	0.21	$	0.66	$	0.84

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		210		212		488		213

Note 11 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Dividends Payable [Table Text Block]

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2019
March 22, 2019	April 5, 2019	$	0.085	$	1,672
May 22, 2019	June 5, 2019	$	0.085	$	1,672
August 21, 2019	September 5, 2019	$	0.085	$	1,691
Fiscal Year 2018
March 22, 2018	April 5, 2018	$	0.070	$	1,351
May 22, 2018	June 7, 2018	$	0.070	$	1,353
August 22, 2018	September 6, 2018	$	0.070	$	1,369
November 20, 2018	December 6, 2018	$	0.070	$	1,372

Note 12 - Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	Nine Months Ended
	September 30,
	2019		2018
	(in thousands)
Cash paid for income taxes, net	$	4,605	$	5,086

Note 13 - Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Nine months ended
	September 30,
	2019			2018
	(in thousands)
Beginning balance	$	72		$	1,301
Additions		-			-
Payments		(59	)		(1,171	)
Change in fair value included in earnings		(13	)		(24	)

Ending balance	$	-		$	106

Note 14 - Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2019

Notes Tables

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Nine months ended
	September 30,
	2019			2018
	(in thousands)
Beginning balance	$	(3,900	)	$	(2,289	)

Other comprehensive income (loss) before reclassifications		(994	)		(1,193	)
Amounts reclassified from accumulated other comprehensive loss		-			-

Ending Balance	$	(4,894	)	$	(3,482	)

Note 1 - Organization and Basis for Presentation (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Number of Operating Segments	1
Operating Lease, Liability, Total	$ 6,421
Operating Lease, Right-of-Use Asset	$ 6,008
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total		$ 7,000
Operating Lease, Right-of-Use Asset		6,500
Accrued Rent		$ (500)
Minimum [Member]
Period of Payments Received from Customers	30 days
Maximum [Member]
Period of Payments Received from Customers	60 days

Note 1 - Organization and Basis for Presentation - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 29,100	$ 24,164	$ 87,062	$ 77,179
Americas [Member]
Revenue	17,698	14,941	51,584	46,885
EMEA [Member]
Revenue	9,452	7,857	29,479	25,685
Asia Pacific [Member]
Revenue	$ 1,950	$ 1,366	$ 5,999	$ 4,609

Note 2 - Income Tax Expense (Details Textual) - USD ($)	9 Months Ended
Note 2 - Income Tax Expense (Details Textual) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Unrecognized Tax Benefits, Ending Balance	$ 766,000	$ 711,000
Domestic Tax Authority [Member]
Open Tax Year	2016 2017 2018
Foreign Tax Authority [Member]
Open Tax Year	2012 2013 2014 2015 2016 2017 2018

Note 2 - Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)	9 Months Ended
	Sep. 30, 2019 USD ($)
Unrecognized tax benefits as of December 31, 2018	$ 711,000
Additions for tax positions of current year	55,000
Additions for tax positions of prior years
Reductions for settlements with taxing authorities
Reductions for lapses of the applicable statutes of limitations
Unrecognized tax benefits as of September 30, 2019	$ 766,000

Note 3 - Inventories and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 1.8	$ 1.7

Note 3 - Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Raw materials	$ 4,916	$ 4,085
Work-in-process	5,037	5,095
Finished products	22,331	16,391
Other deferred costs	4,411	1,817
Total inventory and other deferred costs	$ 36,695	$ 27,388

Note 4 - Acquisitions and Divestitures (Details Textual) € in Millions, $ in Millions							3 Months Ended	9 Months Ended
	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Oct. 22, 2018 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Apr. 05, 2018 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2019	Oct. 22, 2018 EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life								11 years
Reddick Divestiture [Member]
Proceeds from Sale of Productive Assets, Total						$ 7.4
Long-term Purchase Commitment, Period						2 years
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total							$ 5.9
Tru-Incise Valve Cutter [Member]
Business Combination, Consideration Transferred, Total		$ 8.0
Payments to Acquire Businesses, Gross		6.8
Business Combination, Deferred Purchase Consideration, Installment Payment		0.4
Business Combination, Deferred Purchase Consideration		1.2
Acquisition Date Fair Value		$ 1.1
Business Combination ,Fair Value Inputs, Discount Rate		4.19%
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period		15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		14 years 73 days
Cardial [Member]
Business Combination, Consideration Transferred, Total			$ 2.3	€ 2.0
Payments to Acquire Businesses, Gross			1.3	€ 1.1
Business Combination, Deferred Purchase Consideration			$ 0.4						€ 0.4
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			9 years 146 days	9 years 146 days
Business Combination, Consideration Transferred, Liabilities Incurred			$ 0.5	€ 0.5
Deferred Tax Assets, Business Combinations			0.6						€ 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount			$ 1.6	€ 1.4
Applied Medical [Member]
Business Combination, Consideration Transferred, Total					$ 14.2
Acquisition Date Fair Value					$ 3.0
Business Combination ,Fair Value Inputs, Discount Rate					3.75%
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period					15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life					13 years
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs					$ 3.2
Applied Medical [Member] \| Closing Date [Member]
Business Combination, Consideration Transferred, Total					11.0
Applied Medical [Member] \| 12 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					2.0
Applied Medical [Member] \| 24 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 1.2
Applied Medical [Member] \| UNITED STATES
Percentage of Sales by Major Product Lines					60.00%
Applied Medical [Member] \| Foreign [Member]
Percentage of Sales by Major Product Lines					40.00%
Balloon Supply Agreement [Member] \| Reddick Divestiture [Member]
Long-term Purchase Commitment, Period						6 years
Bioligic Cardiac and Vascular Patch of Admedus Ltd [Member] \| Subsequent Event [Member]
Business Combination, Consideration Transferred, Total	$ 15.5
Payments to Acquire Businesses, Gross	14.2
Business Combination, Deferred Purchase Consideration	1.3
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7.8

Note 4 - Acquisitions and Divestitures - Assets Acquired and Liabilities Assumed (Details) € in Thousands, $ in Thousands	Sep. 30, 2019 USD ($)	Jul. 12, 2019 USD ($)	Dec. 31, 2018 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)
Goodwill	$ 32,102		$ 29,868
Tru-Incise Valve Cutter [Member]
Inventory		$ 827
Equipment and supplies		70
Intangible assets		4,727
Goodwill		2,314
Purchase price		$ 7,938
Cardial [Member]
Inventory \| €				€ 2,419
Equipment and supplies \| €				94
Intangible assets \| €				623
Purchase price \| €				1,940
Land and building \| €				750
Bargain purchase gain \| €				€ (1,946)
Applied Medical [Member]
Inventory					$ 739
Equipment and supplies					416
Intangible assets					6,527
Goodwill					6,361
Purchase price					$ 14,043

Note 4 - Acquisitions and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Details) € in Thousands, $ in Thousands				9 Months Ended
	Jul. 12, 2019 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Sep. 30, 2019
Weighted average useful life (Year)				11 years
Tru-Incise Valve Cutter [Member]
Allocated fair value	$ 4,727
Weighted average useful life (Year)	14 years 73 days
Tru-Incise Valve Cutter [Member] \| Customer Relationships [Member]
Allocated fair value	$ 3,865
Weighted average useful life (Year)	16 years
Tru-Incise Valve Cutter [Member] \| Intellectual Property [Member]
Allocated fair value	$ 558
Weighted average useful life (Year)	7 years
Tru-Incise Valve Cutter [Member] \| Noncompete Agreements [Member]
Allocated fair value	$ 201
Weighted average useful life (Year)	5 years
Tru-Incise Valve Cutter [Member] \| Trade Names [Member]
Allocated fair value	$ 103
Weighted average useful life (Year)	7 years
Cardial [Member]
Allocated fair value \| €		€ 623
Weighted average useful life (Year)		9 years 146 days
Cardial [Member] \| Customer Relationships [Member]
Allocated fair value \| €		€ 250
Weighted average useful life (Year)		16 years
Cardial [Member] \| Intellectual Property [Member]
Allocated fair value \| €		€ 237
Weighted average useful life (Year)		5 years
Cardial [Member] \| Noncompete Agreements [Member]
Allocated fair value \| €		€ 46
Weighted average useful life (Year)		5 years
Cardial [Member] \| Trade Names [Member]
Allocated fair value \| €		€ 90
Weighted average useful life (Year)		5 years
Applied Medical [Member]
Allocated fair value			$ 6,527
Weighted average useful life (Year)			13 years
Applied Medical [Member] \| Customer Relationships [Member]
Allocated fair value			$ 4,475
Weighted average useful life (Year)			16 years
Applied Medical [Member] \| Intellectual Property [Member]
Allocated fair value			$ 1,316
Weighted average useful life (Year)			7 years
Applied Medical [Member] \| Noncompete Agreements [Member]
Allocated fair value			$ 530
Weighted average useful life (Year)			5 years
Applied Medical [Member] \| Trade Names [Member]
Allocated fair value			$ 206
Weighted average useful life (Year)			7 years

Note 4 - Acquisitions and Divestitures - Asset Purchase Agreement (Details) - Reddick Divestiture [Member] $ in Thousands	Apr. 05, 2018 USD ($)
Inventory	$ 308
Deferred revenue - transition services agreement	1,081
Goodwill	135
Gain on divestiture	5,876
Consideration received	$ 7,400

Note 5 - Goodwill and Other Intangibles (Details Textual)	9 Months Ended
	Sep. 30, 2019
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Balance at December 31, 2018	$ 29,868
Additions for acquisitions	2,314
Effects of currency exchange	(80)
Balance at September 30, 2019	$ 32,102

Note 5 - Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Gross carrying value	$ 30,905	$ 26,184
Accumulated amortization	14,140	12,492
Net carrying value	16,765	13,692
Product Technology and Intellectual Property [Member]
Gross carrying value	12,286	11,728
Accumulated amortization	6,518	5,726
Net carrying value	5,768	6,002
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	2,349	2,246
Accumulated amortization	1,661	1,561
Net carrying value	688	685
Customer Relationships [Member]
Gross carrying value	13,928	10,065
Accumulated amortization	4,398	3,806
Net carrying value	9,530	6,259
Other Intangible Assets [Member]
Gross carrying value	2,342	2,145
Accumulated amortization	1,563	1,399
Net carrying value	$ 779	$ 746

Note 5 - Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Amortization expense	$ 600	$ 380	$ 1,711	$ 1,213

Note 5 - Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Sep. 30, 2019 USD ($)
2019	$ 573
2020	2,233
2021	2,000
2022	1,796
2023	1,722
2023	$ 1,541

Note 6 - Leases (Details Textual) $ in Thousands	Sep. 30, 2019 USD ($) ft²
Finance Lease, Right-of-Use Asset \| $	$ 0
Lessee, Operating Lease, Discount Rate	5.25%
Leased Automobiles [Member]
Lessee, Operating Lease, Term of Contract	3 years
GERMANY
Lessee, Operating Lease, Renewal Term	5 years
CANADA
Lessee, Operating Lease, Renewal Term	5 years
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility One [Member]
Area of Real Estate Property	27,098
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Two [Member]
Area of Real Estate Property	27,289
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Three [Member]
Area of Real Estate Property	15,642
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Four [Member] \| Massachusetts [Member]
Area of Real Estate Property	12,878
International Operations Headquarter Facility [Member] \| GERMANY
Area of Real Estate Property	16,470
Additional Area of Real Estate Property Added	3,630

Note 6 - Leases - Additional Lease Information (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)
Operating lease cost	$ 486	$ 1,340
Short-term lease cost	71	203
Total lease cost	557	1,543
Cash paid for amounts included in the measurement of operating lease liabilities	498	1,457
Right-of-use assets obtained in exchange for new operating leae liabilities	$ 69	$ 879
Weighted average remaining lease term - operating leases (years) (Year)	4 years 73 days	4 years 73 days
Weighted average discount rate - operating leases	5.25%	5.25%

Note 6 - Leases - Minimum Rental Commitments (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Remainder of 2019	$ 533
2020	1,992
2021	1,854
2022	1,537
2023	1,242
Adjustment to net present value as of September 30, 2019	(737)
Operating Lease, Liability, Total	$ 6,421

Note 7 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Compensation and related taxes	$ 7,086	$ 7,973
Income and other taxes	1,347	2,927
Professional fees	142	43
Deferred revenue		552
Other	4,815	4,352
Total	$ 13,390	$ 15,847

Note 7 - Accrued Expenses and Other Long-term Liabilities - Deferred Revenue (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Balance	$ 552
Revenue recognized upon satisfaction of performance obligations in the period	(552)
Balance

Note 7 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Aquisition-related liabilities	$ 2,089	$ 1,326
Deferred rent		530
Income taxes	561	559
Other	147	196
Total	$ 2,797	$ 2,611

Note 8 - Segment and Enterprise-wide Disclosures (Details Textual)	9 Months Ended
	Sep. 30, 2019
Number of Operating Segments	1

Note 8 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net Sales	$ 29,100	$ 24,165	$ 87,062	$ 77,179
UNITED STATES
Net Sales	16,251	13,937	47,015	43,620
GERMANY
Net Sales	3,074	3,058	9,346	9,421
Other Countries [Member]
Net Sales	$ 9,775	$ 7,170	$ 30,701	$ 24,138

Note 9 - Share-based Compensation (Details Textual) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	385,000	329,000

Note 9 - Share-based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation	$ 655	$ 537	$ 2,095	$ 1,794
Share-based Payment Arrangement, Option [Member]
Stock-based compensation	378	331	1,257	1,111
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	$ 277	$ 206	$ 838	$ 683

Note 9 - Share-based Compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total stock-based compensation	$ 655	$ 537	$ 2,095	$ 1,794
Cost of Sales [Member]
Total stock-based compensation	75	61	233	209
Selling and Marketing Expense [Member]
Total stock-based compensation	155	155	459	429
General and Administrative Expense [Member]
Total stock-based compensation	356	266	1,194	967
Research and Development Expense [Member]
Total stock-based compensation	$ 69	$ 55	$ 209	$ 189

Note 10 - Net Income per Share - Computation of Basic and Diluted Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Basic:
Net income	$ 5,184	$ 4,624	$ 3,513	$ 4,314	$ 8,751	$ 3,853	$ 13,321	$ 16,918
Weighted average shares outstanding (in shares)	19,871			19,503			19,731	19,369
Basic earnings per share (in dollars per share)	$ 0.26			$ 0.22			$ 0.68	$ 0.87
Diluted:
Net income	$ 5,184	$ 4,624	$ 3,513	$ 4,314	$ 8,751	$ 3,853	$ 13,321	$ 16,918
Weighted average shares outstanding (in shares)	19,871			19,503			19,731	19,369
Common stock equivalents, if dilutive (in shares)	507			790			546	889
Shares used in computing diluted earnings per common share (in shares)	20,378			20,293			20,277	20,258
Diluted earnings per share (in dollars per share)	$ 0.25			$ 0.21			$ 0.66	$ 0.84
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)	210			212			488	213

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 11 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		9 Months Ended
	Oct. 21, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Feb. 14, 2019
Common Stock, Dividends, Per Share, Declared		$ 0.085	$ 0.07	$ 0.255	$ 0.21
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared	$ 0.085
Dividends Payable	$ 1.7
Dividends Payable, Date Declared	Oct. 21, 2019
Dividends Payable, Date to be Paid	Dec. 05, 2019
Dividends Payable, Date of Record	Nov. 20, 2019
Stock Repurchase Program [Member] \| Common Stock [Member]
Stock Repurchase Program, Authorized Amount						$ 10.0

Note 11 - Stockholders' Equity - Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Per share amount (in dollars per share)	$ 0.085	$ 0.07	$ 0.255	$ 0.21
Quarterly Dividends 1 [Member]
Record date			Mar. 22, 2019		Mar. 22, 2018
Payment date			Apr. 05, 2019		Apr. 05, 2018
Per share amount (in dollars per share)			$ 0.085		$ 0.07
Dividend payment	$ 1,672		$ 1,672		$ 1,351
Quarterly Dividends 2 [Member]
Record date			May 22, 2019		May 22, 2018
Payment date			Jun. 05, 2019		Jun. 07, 2018
Per share amount (in dollars per share)			$ 0.085		$ 0.07
Dividend payment	1,672		$ 1,672		$ 1,353
Quarterly Dividends 3 [Member]
Record date			Aug. 21, 2019		Aug. 22, 2018
Payment date			Sep. 05, 2019		Sep. 06, 2018
Per share amount (in dollars per share)			$ 0.085		$ 0.07
Dividend payment	$ 1,691		$ 1,691		$ 1,369
Quarterly Dividends 4 [Member]
Record date					Nov. 30, 2018
Payment date					Dec. 06, 2018
Per share amount (in dollars per share)					$ 0.07
Dividend payment					$ 1,372

Note 12 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash paid for income taxes, net	$ 4,605	$ 5,086

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 18, 2016	Sep. 30, 2019	Nov. 10, 2016
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Assets, Fair Value Disclosure		$ 0
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member]
Acquisition Date Fair Value			$ 1,000
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Earn Out Payment [Member]
Business Combination, Contingent Consideration, Liability, Total			4,000
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Non-employee Investors [Member]
Business Combination, Contingent Consideration, Liability, Total			1,100
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Maximum [Member]
Business Combination, Contingent Consideration, Liability, Total			$ 5,100
Fair Value, Inputs, Level 3 [Member] \| ProCol Biologic Graft [Member]
Business Combination Contingent Consideration Measurement as Percentage of Revenue	10.00%
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred	$ 300

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Beginning balance	$ 72	$ 1,301
Additions
Payments	(59)	(1,171)
Change in fair value included in earnings	(13)	(24)
Ending balance		$ 106

Note 14 - Accumulated Other Comprehensive Income Loss - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Balance	$ 130,235	$ 109,770
Balance	142,316	125,347
AOCI Attributable to Parent [Member]
Balance	(3,900)	(2,289)
Other comprehensive income (loss) before reclassifications	(994)	(1,193)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ (4,894)	$ (3,482)